title: Amelioration effects of berberine on diabetic microendothelial injury model by the combination of high glucose and advanced glycation end products in vitro.
abstract: Microvascular complications are much earlier and common in diabetes. Advanced glycation end products (AGEs), together with high glucose, play a key role in the endothelial dysfunction of diabetic vascular complications. So it is of more significance to expedite the therapies to block the formation and/or the effects of AGEs. Berberine has been showed to have anti-diabetic effects, however the effects on diabetic complications were less explored, especially the effects on the microvascular complications and the formation and pathways of AGEs which have not been reported. Therefore, the present study established an in vitro model of diabetic microendothelial (microEC) injury by the combination of high glucose and AGEs to mimic the clinical situations and examine the effects and mechanisms of berberine on high glucose-AGEs-induced microEC injuries and on the formation of AGEs. We prepared AGEs, established the high glucose-AGEs injured microEC models by MTT assay, which was further supported by significantly decreased nitric oxide (NO) release, NO synthase (NOS) and thrombomodulin production with ELISA, western blot and RT-PCR analysis. Berberine treatments showed significant improvements as indicated by significantly increased NO release, NOS and thrombomodulin production. Moreover, we also observed significant inhibition effects of berberine on AGEs formation. We concluded that the in vitro model of diabetic microEC injury could be established by the combination treatments of high glucose and AGEs, while berberine could improve the diabetic microvascular injury in vitro and inhibit the formation of AGEs, suggesting the potential clinical therapies with berberine for diabetes and its vascular complications.
authors.affiliation: Department of Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, Liaoning, China.
authors.forename: Min
authors.initials: M
authors.lastname: Hao
authors.forename: Shu-yuan
authors.initials: SY
authors.lastname: Li
authors.forename: Chang-kai
authors.initials: CK
authors.lastname: Sun
authors.lastname: Jingyu-Xu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lin
authors.forename: Ke-xin
authors.initials: KX
authors.lastname: Liu
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Chuan-xun
authors.initials: CX
authors.lastname: Li
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhou
authors.forename: Jian-ling
authors.initials: JL
authors.lastname: Du
authors.forename: Hua
authors.initials: H
authors.lastname: Li
mesh_terms: D000818:Animals; D001599:Berberine / Q000494:pharmacology* / Q000627:therapeutic use; D002457:Cell Extracts; D002460:Cell Line; D048909:Diabetes Complications / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000293:injuries* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005947:Glucose / Q000494:pharmacology*; D017127:Glycation End Products, Advanced / Q000494:pharmacology*; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D018180:Thrombomodulin / Q000235:genetics / Q000378:metabolism; D057772:Vascular System Injuries / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D002457:Cell Extracts; D017127:Glycation End Products, Advanced; D018180:Thrombomodulin; D001599:Berberine; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D005947:Glucose